Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 53-71 , March 2003

Prevention and management of osteoporosis

Received 1 August 2002 ,Accepted 1 September 2002.

References 

  1. Melton LJ. How many women have osteoporosis now?. Journal of Bone and Mineral Research. 1995;10:175–177
  2. National Osteoporosis Foundation . Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporosis International. 1998;8:S7–S88
  3. Giullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporosis International. 1997;7:407–413
  4. NIH Consensus Development Panel on Osteoporosis . Prevention diagnosis and therapy. Osteoporosis diagnosis and therapy. Journal of the American Medical Association. 2001;285:785–795
  5. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. WHO Technical Report Series 843. Geneva: WHO, 1994.
  6. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. Journal of Clinical Densitometry. 1999;2:343–350
  7. Harper KD, Weber TJ. Secondary osteoporosis: diagnostic considerations. Endocrinology and Metabolism Clinics of North America. 1998;27:325–348
  8. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–1936
  9. Klotzbuecher CM, Ross PD, Landsman PB, et al.  Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. Journal of Bone and Mineral Research. 2000;15:721–727
  10. Bonjour J-P, Theintz G, Law F, et al.  Peak bone mass. Osteoporosis International. 1994;8:S7–S13
  11. Reid IR. The roles of calcium and vitamin D in the prevention of osteoporosis. Endocrinology and Metabolism Clinics of North America. 1998;27:389–398
  12. Recker RR, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. Journal of Bone and Mineral Research. 2000;15:1965–1973
  13. Uusi-Rasi K, Sievanen H, Pasanen M, et al.  Association of physical activity and calcium intake with the maintenance of bone mass in premenopausal women. Osteoporosis International. 2002;13:211–217
  14. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent post-menopausal bone loss? A double-blind, controlled clinical study. New England Journal of Medicine. 1987;316:173–177
  15. McClung MR, Clemmensen B, Daifotis A, et al.  Alendronate prevents post-menopausal bone loss in women without osteoporosis. Annals of Internal Medicine. 1998;128:253–261
  16. The Writing Group for the PEPI Trial . Effects of hormone therapy on bone mineral density: results from the Post-menopausal Estrogen/Progestin Interventions (PEPI) Trial. Journal of the American Medical Association. 1996;276:1389–1396
  17. Elders PJ, Netelenbos JC, Lips P, et al.  Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. Journal of Clinical Endocrinology and Metabolism. 1991;73:533–540
  18. Chapuy MC, Preziosi P, Maamer M, et al.  Prevalence of vitamin D insufficiency in an adult normal population. Osteoporosis International. 1997;7:439–443
  19. Cumming RG, Cummings SR, Nevitt MC, et al.  Calcium intake and fracture risk: results from the Study of Osteoporotic Fractures. American Journal of Epidemiology. 1997;145:926–934
  20. Riggs BL, O'Fallon WM, Muhs J, et al.  Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. Journal of Bone and Mineral Research. 1998;13:168–174
  21. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. Calcified Tissue International. 1990;47:194–201
  22. Recker RR, Hinders S, Davies KM, et al.  Correcting calcium nutritional deficiency prevents spine fractures in elderly women. Journal of Bone and Mineral Research. 1996;11:1961–1966
  23. Chapuy MC, Arlot ME, Duboeuf F, et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine. 1992;327:1637–1642
  24. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of oestrogen and calcitonin on bone mass: review and analysis. American Journal of Clinical Nutrition. 1998;67:18–24
  25. North American Menopause Society . Management of post-menopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002;9:84–101
  26. Wolff I, van Croonenborg JJ, Kemper HC, et al.  The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and post-menopausal women. Osteoporosis International. 1999;9:1–12
  27. Bonaiuti D, Shea B, Iovine R, et al.  Exercise for preventing and treating osteoporosis in post-menopausal women. Cochrane Database System Review. 2002;3:CD000333
  28. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcified Tissue International. 2001;68:259–270
  29. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham Study. American Journal of Epidemiology. 1988;128:1102–1110
  30. Cummings SR, Browner WS, Bauer D, et al.  Endogenous hormones and the risk of hip and vertebral factures among older women. New England Journal of Medicine. 1998;(339):733–738
  31. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;ii:1151–1154
  32. Christiansen C, Riss BJ. 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. Journal of Clinical Endocrinology and Metabolism. 1990;71:836–841
  33. Speroff L, Rowan J, Symonds J, et al.  The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy (CHART study): a randomized clinical controlled trial. Journal of the American Medical Association. 1996;276:1397–1403
  34. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous oestrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Annals of Internal Medicine. 1999;130:897–904
  35. Greendale GA, Espeland M, Slone S, et al.  Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Post-menopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Archives of Internal Medicine. 2002;162:665–672
  36. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term oestrogen treatment. Osteoporosis International. 1995;5:23–29
  37. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. Journal of the American Medical Association. 2001;285:2891–2897
  38. Writing Group for the Women's Health Initiative . Risks and benefits of oestrogen plus progestin in healthy post-menopausal women. Journal of the American Medical Association. 2002;288:321–333
  39. Lufkin EG, Wahner HW, O'Fallon WM, et al.  Treatment of post-menopausal osteoporosis with transdermal oestrogen. Annals of Internal Medicine. 1992;117:1–9
  40. Prior JC, Vignay YM, Schechkter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. New England Journal of Medicine. 1990;323:1221–1227
  41. Abdalla HI, Hart DM, Lindsay R, et al.  Prevention of bone mineral loss in post-menopausal women by norethisterone. Obstetrics and Gynceology. 1985;66:789–792
  42. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and post-menopausal bone loss. Obstetrics and Gynecology. 1999;94:225–228
  43. Powles TJ, Hickish T, Kanis JA, et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and post-menopausal women. Journal of Clinical Oncology. 1996;14:78–84
  44. Delmas PD, Bjarnason NH, Mitlak BH, et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in post-menopausal women. New England Journal of Medicine. 1997;337:1641–1647
  45. Ettinger B, Black DM, Mitlak BH, et al.  Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene. Journal of the American Medical Association. 1999;282:637–645
  46. Barrett-Connor E, Grady D, Sashegyi A, et al.  Raloxifene and cardiovascular events in osteoporotic post-menopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Journal of the American Medical Association. 2002;287:847–857
  47. Cummings SR, Eckert S, Krueger KA, et al.  The effect of raloxifene on risk of breast cancer in post-menopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Journal of the American Medical Association. 1999;281:2189–2197
  48. Gallagher JC, Baylink DJ, Freeman R, McClung MR. Prevention of bone loss with tibolone in post-menopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. Journal of Clinical Endocrinology and Metabolism. 2001;86:4717–4726
  49. Lippuner K, Haenggi W, Birkhauser MH, et al.  Prevention of post-menopausal bone loss using tibolone or conventional peroroal or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. Journal of Bone and Mineral Research. 1997;12:806–812
  50. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Menopause 2000; 7: 215–229.
  51. Alexandersen P, Toussaint A, Christiansen C, et al.  Ipriflavone in the treatment of post-menopausal osteoporosis: a randomized controlled trial. Ipriflavone Multicenter European Fracture Study. Journal of the American Medical Association. 2001;285:1482–1488
  52. Russell RGG, Rogers MG. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97–106
  53. Chesnut CH, McClung MR, Ensrud KE, et al.  Alendronate treatment of the post-menopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelling. American Journal of Medicine. 1995;99:144–152
  54. Borah B, Dufresne TE, Chmielewski PA, et al.  Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. Journal of Bone and Mineral Research. 2002;17:1139–1147
  55. Tonino RP, Meunier PJ, Emkey R, et al.  Skeletal benefits of alendronate: 7-year treatment of post-menopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism. 2000;85:3109–3115
  56. Boivin GY, Chavassieux PM, Santora AC, et al.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687–694
  57. Cranney A, Guyatt G, Krolicki N, et al.  A meta-analysis of etidronate for the treatment of post-menopausal osteoporosis. Osteoporosis International. 2001;12:140–151
  58. Black DM, Cummings SR, Karpf DB, et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541
  59. Cummings SR, Black DM, Thompson D, et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Journal of the American Medical Association. 1998;280:2077–2082
  60. Karpf DB, Shapiro DR, Seeman E, et al.  Prevention of nonvertebral fractures by alendronate: a meta-analysis. Journal of the American Medical Association. 1997;277:1159–1164
  61. Ravn P, Bidstrup M, Wasnich RD, et al.  Alendronate and oestrogen-progestin in the long-term prevention of bone loss: four-year results from the early post-menopausal intervention cohort study. Annals of Internal Medicine. 1999;131:935–942
  62. Bauer DC, Black D, Ensrud K, et al.  Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Archives of Internal Medicine. 2000;160:517–525
  63. Schnitzer T, Bone HG, Crepaldi G, et al.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clinical and Experimental Research. 2000;12:1–12
  64. Cosman F, Cummings S, Lindsay R. How long should patients with osteoporosis be treated with bisphosphonates?. Journal of Women's Health. 2000;9:81–84
  65. Harris S, Watts N, Genant H, et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis. Journal of the American Medical Association. 1999;282:1344–1352
  66. Reginster J-Y, Minne H, Sorensen OH, et al.  Randomized trial of the effects of risedronate on vertebral fractures in women with established post-menopausal osteoporosis. Osteoporosis International. 2000;11:83–91
  67. McClung MR, Geusens P, Miller PD, et al.  Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine. 2001;344:333–340
  68. Mortenson L, Charles P, Bekker PJ, et al.  Risedronate increases bone mass in an early post-menopausal population: two years of treatment plus one year of follow-up. Journal of Clinical Endocrinology and Metabolism. 1998;83:396–402
  69. Brown JP, Kendler DL, McClung MR, et al.  The efficacy and tolerability or risedronate once a week for the treatment of post-menopausal osteoporosis. Calcified Tissue International. 2002; June 27; online publication
  70. Geusens P, McClung M. Review of risedronate in the treatment of osteoporosis. Expert Opinion in Pharmacotherapy. 2001;2:2011–2025
  71. Chesnut CH, Silverman S, Andriano K, et al.  A randomized trial of nasal spray salmon calcitonin in post-menopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. American Journal of Medicine. 2000;109:267–276
  72. Bone H, Greenspan S, McKeever C, et al.  Alendronate and oestrogen effects in post-menopausal women with low bone mineral density. Journal of Clinical Endocrinology and Metabolism. 2000;85:720–726
  73. Harris ST, Eriksen EF, Davidson M, et al.  Effect of combined risedronate and hormone replacement therapies on bone mineral density in post-menopausal women. Journal of Clinical Endocrinology and Metabolism. 2001;86:1890–1897
  74. Johnell O, Scheele WH, Lu Y, et al.  Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in post-menopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism. 2002;87:985–992
  75. Rubin MR, Bilizekian JP. New anabolic therapies in osteoporosis. Current Opinion in Rheumatology. 2002;14:433–440
  76. Neer RM, Arnaud CD, Zanchetta JR, et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. New England Journal of Medicine. 2001;344:1434–1441
  77. Dempster DW, Cosman F, Kurland ES, et al.  Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. Journal of Bone and Mineral Research. 2001;16:1846–1853
  78. Cosman F, Nieves J, Woelfert L, et al.  Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. Journal of Bone and Mineral Research. 2001;16:925–931
  79. Cosman F, Nieves J, Woelfert L, et al.  Alendronate does not block the anabolic effect of PTH in post-menopausal osteoporotic women. Journal of Bone and Mineral Research. 1998;13:1051–1055
  80. Rittmaster RS, Bolognese M, Ettinger MP, et al.  Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. Journal of Clinical Endocrinology and Metabolism. 2000;85:2129–2134
  81. Haguenauer D, Welch V, Shea B, et al.  Fluoride for the treatment of post-menopausal osteoporotic fractures: a meta-analysis. Osteoporosis International. 2000;11:727–738
  82. Mundy G, Garrett R, Harris S, et al.  Stimulation of bone formation in vitro in rodents by statins. Science. 1999;286:1946–1949
  83. van Staa TP, Wegman S, de Vries F, et al.  Use of statins and risk of fractures. Journal of the American Medical Association. 2001;285:1850–1855
  84. Hodgson SF, Watts NB, Bilezikian JP, et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and management of post-menopausal osteoporosis. Endocrine Practice. 2001;7:293–312
  85. Cummings SR, Karpf DB, Harris F, et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. American Journal of Medicine. 2002;112:281–289
  86. Sarkar S, Mitlak BH, Wong M, et al.  Relationships between bone mineral density and the incident vertebral fracture risk with raloxifene therapy. Journal of Bone and Mineral Research. 2002;17:1–10
  87. Clowes JA, Eastell R. The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillière's Clinical Endocrinology and Metabolism. 2000;14:213–232
  88. Bjarnason NH, Sarkar S, Duong T, et al.  Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in post-menopausal osteoporosis. Osteoporosis International. 2001;12:922–930
  89. Marcus R, Holloway L, Wells B, et al.  The relationship of biochemical markers of bone turnover to bone density changes in post-menopausal women: results form the Post-menopausal Estrogen/Progestin Interventions (PEPI) trial. Journal of Bone and Mineral Research. 1999;14:1583–1595
  90. Cummings SR, Palermo L, Browner W, et al.  Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Journal of the American Medical Association. 2000;283:1318–1321
  91. Malmos B, Mortensen L, Jensen MB, et al.  Positive effects of physiotherapy on pain and performance in osteoporosis. Osteoporosis International. 1998;8:215–221
  92. Lyritis GP, Trovan G. Analgesic effects of calcitonin. Bone. 2002;30:71S–74S
  93. Watts NB, Harris ST, Genant HK. Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporosis International. 2001;12:429–437
  94. Harrison JE, Chow R, Dornan J, et al.  Evaluation of a program for rehabilitation of osteoporotic patients (PRO): 4-year follow-up. Osteoporosis International. 1993;3:13–17
  95. McClung MR, Spencer K. Nonpharmacologic therapy for osteoporosis. In:  Rosen CJ editors. Osteoporosis: Diagnostic and Therapeutic Principles. Totowa, NJ: Humana Press Inc; 1996;p. 189–199
  96. Butler M, Norton R, Lee-Joe T, Coggan C. Preventing falls and fall-related injuries among older people living in institutions: current practice and future opportunities. New Zealand Medical Journal. 1998;111:359–361
  97. Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. American Journal of Clinical Nutrition. 2002;75:611–615
  98. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database System Review. 2000;2:CD001255

PII: S1521-690X(02)00080-5

doi: 10.1016/S1521-690X(02)00080-5

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 53-71 , March 2003

Article Tools

* Image Usage & Resolution